Compare Duke Energy Corp (DUK) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Novo Nordisk A/S — how do they compare? Duke Energy Corp trades at $123.5 (market cap $96.05B), while Novo Nordisk A/S trades at $46.32 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.2× Duke Energy Corp's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| DUK | NVO | |
|---|---|---|
Market Cap | $96.05B | $207.85B |
Sector | Utilities | Health |
52-Week High | $133.46 | $63.98 |
52-Week Low | $113.99 | $35.29 |
Enterprise Value | $188.56B | $222.55B |
Dividend Yield | 3.52% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $123.23, up 1.68% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $1.43 exceeding expectations, supported by growing revenue and healthy profit margins. Recent news highlights operational challenges from storms affecting customers but also strategic initiatives including a $35 million equity units offering and data center growth opportunities.
The outlook remains stable with analyst consensus pointing to upside potential (target $136.17) and no sell ratings. Key risks include regulatory scrutiny and capital expenditure pressures, but the company's dividend reliability and infrastructure investments provide long-term stability. The stock presents a balanced opportunity for income-focused investors amid current technical weakness.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
